Ketamine: The Complete UK Guide — Pharmacology, Health Risks, Bladder Syndrome, Dependence, Safeguarding and Treatment (2026)

Introduction: Why Ketamine Demands Urgent Attention

Ketamine is no longer a niche club drug. In the space of a decade it has moved from hospital anaesthetic rooms and festival fields into secondary schools, social housing stairwells, and university common rooms across the United Kingdom. The Office for Health Inequalities and Disparities (OHID) recorded more than 17,000 people entering drug treatment specifically citing ketamine as their primary substance in 2022–23 — a figure that was fewer than 2,000 a decade earlier. Emergency department presentations for ketamine-related harm have surged by nearly 60% since 2020. And behind those statistics lies a hidden clinical catastrophe: ketamine bladder syndrome, an irreversible and profoundly disabling condition that has left teenagers and young adults requiring urological surgery, including total bladder removal.

This treatise is written for Designated Safeguarding Leads, school and college safeguarding teams, health and social care professionals, and parents who want a thorough, evidence-based understanding of what ketamine is, how it works, what it does to the body and mind over time, and what the law, the NHS, and current best practice say about prevention, early intervention, and treatment.

Part I — Pharmacology and History

1.1 Discovery and Medical History

Ketamine was first synthesised in 1962 by chemist Calvin Stevens at Parke-Davis, as a safer alternative to phencyclidine (PCP). It was approved for human use by the US Food and Drug Administration in 1970 and used extensively as a battlefield anaesthetic during the Vietnam War due to its ability to maintain respiration and airway reflexes even at full anaesthetic doses — a critical advantage in the field. It received UK marketing authorisation from what is now the Medicines and Healthcare products Regulatory Agency (MHRA) and remains an essential medicine on the NHS to this day. It is also widely used in veterinary practice, which has historically made it a target for diversion.

In the 1990s ketamine began appearing in UK club culture, emerging alongside MDMA and LSD at raves. Its street profile remained relatively low until the mid-2010s when cheaper supply chains — largely originating from illicit synthesis in China and India — dramatically reduced the street price, making it more accessible than almost any other Class B substance.

1.2 Mechanism of Action: The NMDA Receptor

Ketamine's primary mechanism is non-competitive antagonism of the NMDA (N-methyl-D-aspartate) glutamate receptor. NMDA receptors are ion channels that normally open when glutamate — the brain's main excitatory neurotransmitter — binds to them. By blocking the channel from the inside (a mechanism called open-channel block), ketamine prevents the normal flow of calcium ions into the neurone, disrupting synaptic transmission across a wide range of brain circuits.

This action produces its characteristic dissociative effects: perception of self and environment become separated. At sub-anaesthetic doses this produces floating sensations, perceptual distortions, and euphoria. At higher doses, full dissociation occurs — the user is conscious but entirely disconnected from reality and unable to act volitionally (the "K-hole").

Ketamine also acts on:

• Opioid receptors (mu, delta, kappa) — contributing to analgesia and rewarding effects
• Sigma receptors — which may mediate some of the hallucinatory and psychotomimetic properties
• Monoamine systems (dopamine, serotonin, noradrenaline) — important in its antidepressant properties and potential for abuse
• Muscarinic receptors — explaining the bronchodilation that makes it safe in emergency airway management

Ketamine exists as two enantiomers — S-ketamine and R-ketamine. The S-isomer (esketamine, marketed as Spravato) is approximately twice as potent as the R-isomer and has received NICE approval in the UK as an adjunct for treatment-resistant depression. This legitimate therapeutic use has increased general awareness of — and potentially normalised — the drug among some groups.

1.3 Pharmacokinetics

When snorted (insufflated) — the most common recreational route — ketamine has a bioavailability of approximately 45–50%, with onset within 5–15 minutes and effects lasting 45–90 minutes. Oral ingestion reduces bioavailability to around 20%, producing slower onset. Intramuscular injection delivers near-complete bioavailability with onset under 5 minutes. Intravenous use (rare recreationally) produces effects within 30 seconds.

Ketamine is primarily metabolised in the liver to norketamine (which retains pharmacological activity at approximately one-third the potency) and then to dehydronorketamine, which is renally excreted. Half-life is approximately 2–3 hours. Chronic use upregulates CYP3A4 liver enzymes, leading to faster clearance — a mechanism that drives tolerance and dose escalation.

Part II — The UK Epidemic in Data

2.1 Treatment Demand

The National Drug Treatment Monitoring System (NDTMS), administered by OHID, provides the most comprehensive picture of treatment need. Key findings from the 2022–23 annual report:

2.2 Prevalence (ONS Drug Misuse Survey 2024)

The ONS Crime Survey for England and Wales 2023–24 reports:

• 1.3% of adults (16–59) used ketamine in the past year — the highest recorded figure, surpassing ecstasy in the 16–24 age band
• Among 16–24-year-olds, 4.2% reported past-year use and 8.3% reported lifetime use
• Use in this age band has more than doubled since 2019–20 (1.9%), the sharpest proportional rise of any substance measured
• Reported availability at street level is high: in a 2024 Global Drug Survey panel, 94% of UK ketamine users described it as easy or very easy to obtain

2.3 Hospital Admissions

NHS England Hospital Episode Statistics (HES) data show:

• 4,812 ketamine-related emergency admissions in 2022–23, up 59% from 3,028 in 2019–20
• Admissions for ketamine-associated uropathy (bladder and urinary tract damage) account for approximately 30% of this total
• A significant minority require urological surgery, with cystectomy rates in the under-30 cohort rising year-on-year
• Deaths in which ketamine was implicated: 202 in England and Wales in 2022 (ONS mortality data, where ketamine was a contributory factor, frequently alongside alcohol or benzodiazepines)

2.4 Street Price and Supply Chains

Ketamine is sold in the UK predominantly as a white or off-white crystalline powder, often in small press-seal bags or "wraps". Typical street prices in 2024–25 range from £15–£30 per gram, with bulk purchases available for as little as £10 per gram. This low cost — cheaper per hour of intoxication than alcohol in many contexts — is a significant driver of its appeal to young people.

The majority of illicitly available ketamine in the UK is derived from precursor diversion and illicit synthesis in South and East Asia, primarily China and India, before being trafficked through European distribution networks. A smaller proportion results from pharmaceutical diversion — veterinary supplies in particular remain a target. Purity testing by WEDINOS (Wales and England Drug Identification Network Offering Support) and The Loop consistently shows street ketamine at 50–95% purity, meaning adulterants are common, including levamisole, caffeine, and in some samples, NBOMe compounds.

Part III — Routes of Use and What They Signal

Part IV — Acute Effects: From Micro-dose to K-Hole

4.1 Dose-Dependent Effects

The effect profile of ketamine varies enormously by dose. Recreational users typically titrate dose to achieve the desired level of dissociation, making it particularly difficult to predict effect in a group setting:

4.2 The K-Hole: Clinical and Safeguarding Perspective

The K-hole is not simply "being very high". It represents a near-complete dissociation of consciousness from sensory input and motor control. Users in a K-hole are unable to protect their own airway if they vomit, at risk of hypothermia if outdoors, and may be mistaken for unconscious or even dead. They are also completely unable to consent to any interaction — making K-hole states a specific and serious safeguarding risk, particularly in the context of sexual exploitation.

A person emerging from a K-hole typically experiences significant disorientation lasting 30–60 minutes, and may be emotionally distressed, frightened, or highly suggestible. Emergency response: place in the recovery position, call 999, monitor breathing. Do not attempt to "walk off" ketamine intoxication; it must be allowed to clear naturally.

Part V — Long-Term Health Consequences

5.1 Ketamine Bladder Syndrome (KBS) / Ketamine Cystitis

Ketamine bladder syndrome is arguably the most alarming chronic complication of regular ketamine use and is unique among recreational drugs in its mechanism and severity. The condition was first described in the medical literature in 2007 (Shahani et al., BJU International) and has since been documented in thousands of users worldwide.

Prevalence: Studies vary, but Winstock et al. (2012) and follow-up literature suggest approximately 20–30% of regular users (defined as weekly or more frequent use) develop clinically significant KBS. Onset can occur within months of regular use. Young people appear to be at higher risk due to lower body mass and potentially heavier use relative to body weight.

Safeguarding implication: A young person presenting to a GP or A&E with recurrent unexplained pelvic pain, urinary symptoms, or blood in the urine should prompt a sensitive enquiry about ketamine use. Many young people are deeply embarrassed and may have been suffering for months or years. NICE clinical pathway guidance on unexplained lower urinary tract symptoms in young people (NG7) does not yet explicitly reference ketamine — this is a known gap in current guidance that clinicians should be alert to.

5.2 Neuropsychological and Cognitive Effects

Chronic ketamine use produces measurable changes in brain structure and function, documented through neuroimaging studies:

• Prefrontal cortex atrophy: reduced grey matter volume in frontal regions associated with impulse control, decision-making, and working memory (Morgan et al., Neuropsychopharmacology, 2014)
• White matter integrity: diffusion tensor imaging shows reduced fractional anisotropy in tracts connecting the prefrontal cortex, thalamus, and hippocampus — pathways critical for memory consolidation
• Verbal episodic memory: the most consistently impaired cognitive domain in chronic users; impairment persists for at least one year after cessation in some studies
• Attentional and executive function: deficits in sustained attention, task-switching, and planning comparable in magnitude to those seen in early psychosis
• Psychosis risk: ketamine is a well-established pharmacological model for schizophrenia at the research level. Chronic recreational use significantly elevates the risk of persistent psychotic symptoms, particularly in those with a family history of psychotic illness. ONS mortality data identify schizophrenia spectrum disorders as a risk factor disproportionately present in deceased ketamine users

A crucial point for safeguarding professionals: cognitive deficits from ketamine use can mimic or mask learning disabilities, ADHD, or conduct disorder in educational settings. A young person who appears to have suddenly developed concentration difficulties, social withdrawal, or poor emotional regulation should prompt enquiry about drug use, including ketamine.

5.3 Cardiovascular and Other Physical Effects

• Tachycardia and hypertension: ketamine is a sympathomimetic; it raises heart rate and blood pressure acutely. Combined with alcohol, MDMA, or cocaine this creates significant cardiac risk
• Laryngospasm: rare but potentially fatal; may occur during emergence from anaesthesia-level doses without airway management
• Liver damage: elevated liver enzymes are common in heavy users; frank hepatotoxicity is associated with polysubstance use, particularly with alcohol
• Nasal septum damage: chronic insufflation causes necrosis of the nasal cartilage; perforation of the nasal septum has been documented in long-term users
• Accident and injury: the profound anaesthetic and analgesic properties of ketamine mean that users who are injured (e.g., falls, burns) may not register pain appropriately, masking the severity of injury

Part VI — Dependence and Withdrawal

6.1 The Nature of Ketamine Dependence

Ketamine dependence is primarily psychological, though evidence for a physiological withdrawal syndrome is growing. Tolerance develops rapidly: a user may progress from recreational doses of 100–200 mg to daily use of 2–5 grams within months. The cost of maintaining this habit is £30–£150 per day, which drives acquisitive crime, debt, and in some cases exploitation.

The drug's dissociative properties are particularly reinforcing in young people experiencing trauma, anxiety, depression, or adverse childhood experiences (ACEs). Ketamine provides a reliable and rapid escape from emotional pain — a "chemical dissociation" that mirrors the dissociation sometimes associated with trauma itself. This creates a mutually reinforcing cycle: trauma drives use; use impairs emotional regulation, worsening trauma responses; and the physiological consequences (particularly urinary pain) compound distress.

6.2 Withdrawal Syndrome

Unlike opioids, ketamine withdrawal is not typically life-threatening, but it is highly distressing and is a significant barrier to treatment engagement:

• Psychological symptoms: intense cravings, anxiety, panic attacks, dysphoria, depression (sometimes severe), irritability, agitation
• Cognitive symptoms: difficulty concentrating, confusion, memory problems
• Physical symptoms: insomnia, nausea, sweating, tremor (in heavy users), fatigue
• Onset and duration: symptoms typically begin within 24–72 hours of cessation and peak at 3–7 days. Psychological symptoms, particularly depression and cravings, may persist for weeks to months
• Risk of relapse: without structured support, relapse rates in the acute withdrawal period are very high; some patients describe returning to use primarily to manage urinary pain, creating a particularly tragic clinical scenario

There are currently no MHRA-approved or NICE-recommended pharmacological treatments specifically for ketamine dependence. Management is symptom-based: benzodiazepines for acute anxiety (with caution given dependence risk), antidepressants for persistent low mood, and symptom management for urinary pain. This underscores the importance of psychosocial treatment approaches.

Part VII — Polydrug Use: Compounding Risk

Ketamine is rarely used in isolation. The 2024 Global Drug Survey found that 86% of UK ketamine users reported using it in combination with at least one other substance. Key combinations and their risks:

Part VIII — Why Young People Are Particularly Vulnerable

• The developing brain: the prefrontal cortex, which governs impulse control, risk assessment, and long-term planning, does not fully mature until the mid-twenties. NMDA receptor antagonism by ketamine disrupts exactly the pathways that are most active and most sensitive during adolescent brain development. Animal studies consistently show that exposure during adolescence produces more severe and longer-lasting cognitive impairments than adult exposure
• Low perceived risk: unlike heroin or crack cocaine, ketamine does not carry significant social stigma among young people. Many view it as a "soft" dissociative — preferable to "harder" drugs. The DfE's own data (RSHE 2024 review) note a significant gap between prevalence of ketamine use and young people's perception of its risk
• Social media normalisation: TikTok and Instagram content trivialising ketamine use — including K-hole videos framed as humorous — has been documented by the Internet Watch Foundation and the Children's Commissioner. CEOP and NCA county lines intelligence also document dealers using social media to market to young people
• Festival and nightlife context: while pub and club culture have long been associated with alcohol, ketamine features heavily at music festivals, raves, and house parties attended by young people. Its low price point and easy concealment (a gram fits in a key) make it particularly accessible
• Adverse childhood experiences: NDTMS data consistently show a high rate of ACEs (abuse, neglect, domestic violence, parental substance misuse) among those entering treatment for ketamine. Dissociation is a core trauma response; ketamine may be actively sought as a pharmacological form of this
• County lines exploitation: NCA and Catch22 data document ketamine being distributed through county lines networks, with young people used as drug runners. A young person found in possession of multiple wraps of ketamine may be a victim of CCE rather than a simple possession case

Part IX — Recognising Ketamine Use: Warning Signs by Audience

9.1 For Parents

9.2 For Teachers and School Staff

9.3 For Health and Social Care Professionals

Part X — Safeguarding Duties and the Law

10.1 Your Safeguarding Obligations (KCSIE 2024 / Working Together 2023)

Ketamine use by a child or young person is a child protection concern under Working Together to Safeguard Children 2023. Under the Keeping Children Safe in Education (KCSIE) 2024 statutory guidance, all school staff have a duty to:

• Report concerns to the Designated Safeguarding Lead (DSL) without delay
• Not investigate independently or promise confidentiality
• Record concerns factually with time, date, and exact words used by the young person

DSLs must consider whether the concern meets the threshold for a referral to the MASH (Multi-Agency Safeguarding Hub) or Children's Social Services. Drug use alone does not automatically require a statutory referral, but the presence of any of the following escalates the concern significantly:

• Evidence or suspicion of CCE or CSE
• Physical harm (including KBS, unconsciousness, or injuries sustained while intoxicated)
• Significant deterioration in welfare, including mental health crisis
• Parental drug use or a chaotic home environment compounding the risk
• The young person being found or suspected to be in possession of large quantities (potential supply)

10.2 Legal Status

10.3 County Lines and Exploitation

The NCA's 2023 county lines strategic assessment identifies ketamine as a growing secondary commodity distributed alongside Class A drugs in county lines operations. Young people who are found with ketamine should be assessed for CCE indicators as set out in the Home Office's Statutory Guidance on Child Criminal Exploitation (2023):

• Going missing frequently or returning home late
• Unexplained money, gifts, or new phones
• Association with older individuals or unfamiliar adults
• Evidence of being controlled (scripted speech, fear of someone being told)
• Physical injuries not explained by stated cause

Part XI — Having the Conversation

Research consistently shows that young people are more likely to disclose and engage with support when approached with curiosity rather than judgment. Motivational interviewing principles are most effective:

Always end a conversation with a clear next step and a specific offer of support, even if the young person denies use. "If you ever do want to talk, you know where I am" is not sufficient — offer a specific follow-up: "I'll check in with you on Friday."

Part XII — Treatment and Referral Pathways